Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.52 |
| ▸ | CTSK | P43235 | 8/20 | 0.52 |
| ▸ | CTSB | P07858 | 5/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15776420 | 0.87 | CTSS (0.50) | CTSSCTSKCTSBCTSLSIGMAR1 | |
| SCHEMBL6463767 | 0.84 | LMNA (0.48) | CTSSCTSKCTSBCTSLCA12 | |
| SCHEMBL16384584 | 0.79 | TDP1 (0.43) | CTSSCTSKCTSBCTSL | |
| SCHEMBL12475422 | 0.77 | CTSS (0.42) | CTSSCTSKCTSBCTSL | |
| SCHEMBL572740 | 0.75 | IDO1 (0.60) | CTSSCTSKSIGMAR1CA12CA1 | |
| SCHEMBL6467403 | 0.74 | SIGMAR1 (0.41) | CTSSCTSKSIGMAR1CA12CA1 | |
| Propionic Acid SCHEMBL8529443 | 0.73 | CTSK (0.57) | CTSSCTSKSIGMAR1CA12CA1 | |
| SCHEMBL893896 | 0.73 | SIGMAR1 (0.53) | CTSSCTSKSIGMAR1CA12CA1 | |
| SCHEMBL4583683 | 0.73 | POLB (0.65) | CTSKSIGMAR1IDO1 | |
| SCHEMBL27647644 | 0.72 | CTSK (0.43) | CTSSCTSKSIGMAR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSS 9/4885CTSK 32/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.